Little Green Pharma: Telaleaf and Little Green Pharma sponsor the first cannabis certificate course for doctors in Germany

0
24

New York, NY September 22, 2021 – (PR.com) – Telaleaf Health Inc. (“Telaleaf” or the “Company”), a telemedicine company that is revolutionizing the care of patients with cannabis, is pleased to announce a joint sponsorship with a leading global medical cannabis company, Little Green Pharma Ltd. (or “LGP”), for the first certificate course for doctors, pharmacists and relevant professionals interested in prescribing and treating cannabis-based products. The course is organized by Dresden International University in Germany.

The course “The AZ of cannabis-based therapy: Basics and practical application of cannabis-based drugs in medical practice and pharmacy” is a comprehensive, practice-oriented and interdisciplinary certificate course for doctors, which provides in-depth knowledge in all aspects of cannabis therapy, doctors and pharmacists for the appropriate and responsible therapeutic use of all currently prescription cannabis-based drugs. After completing the course, the Saxon State Medical Association will award advanced training points if you have the appropriate professional affiliation.

The course curriculum is developed, directed and instructed by three leading scientific and clinical experts in cannabis medicine: Dr. Franjo Grotenhermen, Dr. Kristen Müller-Vahl and Dr. Dennis Stracke. The many years of individual and combined clinical, practical and scientific experience of these lecturers will be of immense value to the course participants, as will their excellent knowledge of new cannabis laws and the current political and legal landscape in Germany, Europe and beyond.

Dr. Franjo Grotenhermen is a world-renowned guide and expert in the therapeutic use of cannabinoids. He has been chairman of the Cannabis Association (ACM) and founder and CEO of the International Association for Cannabinoid Medicines (IACM) for over 20 years. His book “Cannabis Healing” is considered to be an authoritative guide for the therapeutic use of medicinal cannabis. His expertise is highly regarded and sought after by government agencies, pharmaceutical companies and international institutions such as the World Health Organization and the American Herbal Pharmacopoeia.

Dr. Kirsten Müller-Vahl is a specialist in neurology and adult psychiatry. She is a professor and executive senior physician at the Clinic for Psychiatry, Social Psychiatry and Psychotherapy at the Hannover Medical School. Her academic work includes the role of the endocannabinoid system in psychiatric disorders and treatment studies with cannabinoid modulators and cannabis-based drugs. She has led several clinical studies examining the effectiveness of cannabis-derived drugs. She is regularly invited as an expert in the German Bundestag to hearings on the new German cannabis law.

Dr. Dennis Stracke is Head of Pharmacy Neurology and Rare Diseases, Medios Apotheke Anike Oleski in Berlin, as well as a board member of the Association of Cannabis Supplying Pharmacies (VCA) and the Scientific Advisory Board of the Federal Association of Pharmaceutical Cannabinoid Companies (BPC.). ).

Gavin Treanor, Telaleaf CEO stated, “This certification comes at a time when doctors at all levels of cannabis-based education are desperately needed. With the aim of meeting that need through quality education, Telaleaf has partnered with Little Green Pharma to provide physicians and practitioners with easy access to expert training from the world’s most respected pioneers and leaders in cannabis-based medicine today. “

“As the cannabis field continues to develop, there will be an ongoing need for education, training, and pedagogy for doctors and practitioners who are not only dedicated and flexible, but also highly developed. The blended learning approach of our degree program combines self-study and intensive face-to-face and online group work in order to create ideal conditions for the acquisition and application of skills. Telaleaf believes that proper healthcare training improves patient care and experience. Success in cannabis medicine begins with educational models that bridge the gap between theoretical and practical application to raise the clinical standard among clinicians for the appropriate therapeutic use of cannabis-based products. “

Paul Long, LGP’s chief operations officer, said, “At LGP, we strongly believe that quality education is one of the main driving forces behind building the global medical cannabis industry, Telblatt. In our experience, educated doctors often become strong advocates of medical cannabis therapy, and we believe that this training will help give German health professionals the confidence to prescribe medical cannabis for their patients. “

The first certificate course starts on September 30th, 2021 and is now fully booked. To register for the next course, go to: telaleaf.com/doctors.

About Telaleaf
Telaleaf is a telemedicine company that is revolutionizing the delivery of cannabis care by connecting patients with experienced doctors trained in cannabis-based medicine who conduct virtual doctor visits. Our goal is to improve patient outcomes by enhancing the patient experience with cutting edge technology, simplicity, low cost and expert training for doctors and practitioners for the most advanced virtual care in cannabis medicine.

About Little Green Pharma
Little Green Pharma is a global leader in medical cannabis with major manufacturing facilities in Australia and Europe. Our goal is to improve patient access to GMP quality cannabis medicines around the world and change lives for the better. In order to achieve this, we place great emphasis on supporting doctors with ongoing education about treatment benefits and the prescribing process to make it as easy as possible.

For more information, please contact:
Email: info@telaleaf.com
Phone: 1-647-493-8641

Contact information:
Telaleaf Gavin Treanor
1-647-493-8641
Contact by email
www.telaleaf.com

Read the full story here: https://www.pr.com/press-release/845119

Press release distributed by PR.com

Copyright © 2021 PR.com and its licensors, source US press releases